<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02152592</url>
  </required_header>
  <id_info>
    <org_study_id>11524</org_study_id>
    <secondary_id>2006-003545-17</secondary_id>
    <nct_id>NCT02152592</nct_id>
  </id_info>
  <brief_title>Controlled-Release Oxycodone Versus Naproxen at Home After Ambulatory Surgery: A Randomized Controlled Trial</brief_title>
  <official_title>Controlled-Release Oxycodone Versus Naproxen at Home After Ambulatory Surgery: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      the primary objective of this study is to assess and compare the efficacy, safety and&#xD;
      benefits of Controlled Release (CR) oxycodone/paracetamol with our current pain protocol&#xD;
      (paracetamol/naproxen) in the treatment of acute postoperative pain at home after painful&#xD;
      day-case surgery. We hypothesize that ambulatory patients postoperatively treated with&#xD;
      oxycodone/paracetamol will achieve better pain relief with equal side effects compared to&#xD;
      patients treated with paracetamol/naproxen.&#xD;
&#xD;
      Our second goal is to assess analgesic adherence in the outpatient setting.&#xD;
&#xD;
      Endpoints:&#xD;
&#xD;
      Primary endpoints: pain intensity (Visual analogue scale) Secondary endpoints: -&#xD;
      side-effects/ adverse effects of study medication&#xD;
&#xD;
        -  patient satisfaction with pain treatment&#xD;
&#xD;
        -  compliance to study medication&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      Patients scheduled for painful ambulatory surgery (knee arthroscopy, unilateral open or&#xD;
      laparoscopic inguinal hernia repair) will be enrolled in an open randomized controlled trial&#xD;
      (RCT) at our pre-assessment clinic.&#xD;
&#xD;
      Subjects will be enrolled by a study nurse and will be randomized into one of three study&#xD;
      treatment groups using a computer-generated list. Patients in group 1 (PCM/NAPR) are assigned&#xD;
      to postoperative analgesia using naproxen 500 mg orally twice a day for 48 hours&#xD;
      postoperatively. Patients assigned to group 2 (PCM/Oxy1) receive CR oxycodone 10 mg orally&#xD;
      twice a day for 24 hours. Patients in group 3 (PCM/Oxy2) are postoperatively treated witch CR&#xD;
      oxycodone 10 mg orally twice a day for 48 hours. All patients also receive paracetamol 1000&#xD;
      mg orally four times a day for 48 hours postoperatively.&#xD;
&#xD;
      Recovery after discharge will be assessed using a diary for up to 48 hours after surgery.&#xD;
      Three times a day, patients have to rate pain at rest and movement (VAS), fatigue, nausea,&#xD;
      vomiting, pruritus, miction problems, pyrosis, and abdominal complaints. Furthermore,&#xD;
      compliance to the use of the study medication will be assessed by checking whether the&#xD;
      patients took the study medication as prescribed and if any other pain medication was used.&#xD;
      Compliance will be assessed three times a day and patients will be divided into three groups&#xD;
      according to medication use: always = full compliance, sometimes = partial compliance, or&#xD;
      never = no compliance.&#xD;
&#xD;
      Finally, overall satisfaction with the postoperative pain treatment will be assessed (score&#xD;
      0-10).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>a difference on a pain visual analogue scale between study groups</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>a difference of 15mm or more on a visual analogue scale between three study groups is considered clinically relevant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse effects of study medication</measure>
    <time_frame>up to 48 hours</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adherence to study medication</measure>
    <time_frame>up to 48 hours</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Postoperative Pain After Ambulatory Surgery</condition>
  <arm_group>
    <arm_group_label>PCM/NAPR group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>paracetamol 1000 mg orally four times a day for 48 hours postoperatively and naproxen 500 mg orally twice a day for 48 hours postoperatively (standard hospital pain protocol for treatment of acute postoperative pain at home after painful day-case surgery)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCM/Oxy1 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Controlled Release oxycodone 10 mg orally twice a day for 24 hours and paracetamol 1000 mg orally four times a day for 48 hours postoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCM/Oxy2 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CR oxycodone 10 mg orally twice a day for 48 hours and paracetamol 1000 mg orally four times a day for 48 hours postoperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCM/Oxy1</intervention_name>
    <description>Controlled Release oxycodone 10 mg orally twice a day for 24 hours</description>
    <arm_group_label>PCM/Oxy1 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCM/Oxy2</intervention_name>
    <description>CR oxycodone 10 mg orally twice a day for 48 hours</description>
    <arm_group_label>PCM/Oxy2 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled for painful ambulatory surgery (knee arthroscopy, unilateral open&#xD;
             or laparoscopic inguinal hernia repair)&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical classification I or II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cognitive impairment,&#xD;
&#xD;
          -  preoperative pharmacologic pain treatment&#xD;
&#xD;
          -  allergy to or a contraindication for taking the study medication (e.g. paracetamol,&#xD;
             oxycodone, naproxen or another NSAID)&#xD;
&#xD;
          -  porphyria&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
&#xD;
          -  history of severe renal, hepatic, pulmonary, or cardiac failure&#xD;
&#xD;
          -  current symptoms or history of gastrointestinal bleeding, ileus or chronic obstipation&#xD;
&#xD;
          -  history of substance abuse, or use of medication with a suppressive effect on the&#xD;
             central nervous system&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Anesthesiology, Maastricht University Medical Center+, The Netherlands</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2014</study_first_posted>
  <last_update_submitted>May 28, 2014</last_update_submitted>
  <last_update_submitted_qc>May 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maastricht University Medical Center</investigator_affiliation>
    <investigator_full_name>Bjorn Stessel</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Postoperative pain</keyword>
  <keyword>Ambulatory surgery</keyword>
  <keyword>NSAIDS</keyword>
  <keyword>CR Oxycodone</keyword>
  <keyword>Compliance to study medication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

